



PTO/SB/08a (06-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/790,488
		Filing Date	March 1, 2004
		First Named Inventor	Sherman
		Group Art Unit	1614
Examiner Name	Delacroix-Muirhead, Cybille TIMOTHY BETTON		
Sheet 1 of 1	Attorney Docket Number	AM-101314USA	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
748	US30	2003/008923-A1	01-09-2003	Dukart, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -	Number ⁴ -Kind Code ⁵ (if known)			
748	F5	WO	02/098416	12-12-2002	Wyeth Corp.	
748	F6	WO	02/080975	10-17-2002	Wyeth Corp.	
748	F7	WO	02/40000	05-23-2002	Wyeth Corp.	
748	F8	WO	03/020266	03-13-2003	Wyeth Corp.	

Examiner Signature	<i>Timothy E. Betton</i>	Date Considered	7/20/07
--------------------	--------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/790,488		
		Filing Date	March 1, 2004		
		First Named Inventor	Sherman		
		Group Art Unit	unassigned 1614		
Examiner Name	unassigned TIMOTHY BETTON				
Sheet	1	of	6	Attorney Docket Number	AM-101314USA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
TJB	US1	3,929,992	12-30-1975	Surendra N. Sehgal, et al.	
TJB	US2	3,993,749	11-23-1976	Surendra N. Sehgal, et al.	
TJB	US3	4,401,653	08-30-1983	Chee P. Eng	
TJB	US4	4,885,171	12-05-1989	Surendra N. Sehgal, et al.	
TJB	US5	5,078,999	01-07-1992	Linda M. Warner, et al.	
TJB	US6	5,080,899	01-14-1992	Robert J. Sturm, et al.	
TJB	US7	5,100,899	03-31-1992	R. Calne, et al.	
TJB	US8	5,206,018	04-27-1993	Surendra N. Sehgal, et al.	
TJB	US9	5,286,730	02-15-1994	Craig E. Caufield, et al.	
TJB	US10	5,286,731	02-15-1994	Craig E. Caufield, et al.	
TJB	US11	5,288,711	02-22-1994	Robert D. Mitchell, et al.	
TJB	US12	5,321,009	06-14-1994	William L. Baeder, et al.	
TJB	US13	5,362,718	11-08-1994	Jerauld S. Skotnicki, et al.	
TJB	US14	5,387,589	02-07-1995	Prasad S. Kulkarni	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
TJB	F1	EP - 0 525 960 - A1	02-03-1993	Glenn A. Miller, et al.		
TJB	F2	WO02/066019 - A2	08-29-2002	Novartis AG		
TJB	F3	WO99/52514 - A	10-21-1999	Eli Lilly and Company		X
TJB	F4	WO02/13802 - A2	02-21-2002	American Home Product		

Examiner Signature		Date Considered	7/22/07
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/790,488
				Filing Date	March 1, 2004
				First Named Inventor	Sherman
				Group Art Unit	unassigned 1614
Examiner Name	unassigned TIMOTHY BETTON				
Sheet	2	of	6	Attorney Docket Number	AM-101314USA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
7EB	US15	5,496,832	03-05-1996	Jay J. Armstrong	
7EB	US16	5,516,781	05-14-1996	Randall E. Morris	
7EB	US17	5,561,138	10-01-1996	Jay J. Armstrong	
7EB	US18	2002/0091137-A1	07-11-2002	Dukart, et al.	
7EB	US19	5,066,493	11-19-1991	S.N. Sehgal, et al.	
7EB	US20	2002/0183239-A1	12-05-2002	Gibbons, et al.	
7EB	US21	2002/0183240-A1	12-05-2002	Gibbons, et al.	
7EB	US22	2003/0050222-A1	03-13-2003	Rabindran, et al.	
7EB	US23	6,002,008	12-14-1999	Wissner, et al.	
7EB	US24	6,277,983	08-21-2001	Shaw, et al.	
7EB	US25	6,617,333-B2	09-09-2003	Rabindran, et al.	
7EB	US26	2002/0198137-A1	12-26-2002	Dukart, et al.	
7EB	US27	5,728,710	03-17-1998	Luengo, Juan	
7EB	US28	2003/0153593-A1	08-14-2003	Dukart et al.	
7EB	US29	60/552,122	03-11-2004	Bayever et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	7/23/07
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.


SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/790,488		
		Filing Date	March 1, 2004		
		First Named Inventor	Sherman		
		Group Art Unit	unassigned 1614		
		Examiner Name	unassigned TIMOTHY BETTON		
Sheet	3	of	6	Attorney Docket Number	AM-101314USA

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
TEB	L1	S.N. SEHGAL, et al., Rapamycin (AY-22,989), A New Antifungal Antibiotic, II. Fermentation, Isolation and Characterization, J. Antibiot., October 1975, 727-732, 28		
TEB	L2	C.V. VEZINA, et al., Rapamycin (AY-22,989), A New Antifungal Antibiotic, I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle, J. Antibiot., October 1975, 721-726, 28		
TEB	L3	H.A. BAKER, et al., Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In Vitro and In Vivo Evaluation, J. Antibiot., June 1978, 539-545, 31(6)		
TEB	L4	M.J. STARUCH, et al., FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, FASEB, 1989, 3411, 3		
TEB	L5	F.J. DUMONT, et al., Rapamycin Blocks the Immunosuppressive Effect of FK506 But Not That of Cyclosporin A, FASEB, 1989, 5256, 3		
TEB	L6	R.Y. CALNE, et al., Prolonged Survival of Pig Orthotopic Heart Grafts Treated with Cyclosporin A, The Lancet, June 3, 1978, 1183-1185		
TEB	L7	R. MARTEL, et al., Inhibition of the immune response by rapamycin, a new antifungal antibiotic, Can. J. Physiol. Pharmacol., February 1977, 48-51, 55		
TEB	L8	J. ALEXANDRE, et al., Rapamycin and CCI-779, Bull. Cancer, October 1999, pages 808-811, 86(10) (Only abstract of attached article has English translation)		
TEB	L9	A. PERREN, et al., Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast, Am. J. Pathology, October 1999, pages 1253-1260, 155, No. 4		
TEB	L10	J.E. DANCEY, et al., Rapamycin-Sensitive Signal-Transduction Pathways: Protein Translation Control of Cell Proliferation, ASCO Educational Book, Spring 2000, pages 68-75		
TEB	L11	M. HIDALGO, et al., The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene, December 27, 2000, 6680-6686, 19		
TEB	L12	E.A. SAUSVILLE, et al., New Agents-Noncytotoxins, Antiangiogenesis, ASCO Educational Book, Fall 1998, pages 112-117		
TEB	L13	T. SCHMELZLE, et al., TOR, a Central Controller of Cell Growth, Cell, October 13, 2000, pages 253-262, 103		
TEB	L14	J. ALEXANDRE, et al., "CCI-779, a new rapamycin analog, has antitumor activity at doses inducing only mild cutaneous effects and mucositis; early results of an ongoing phase 1 study", Proceedings of the 10th NCI/EORTC/AACR Symposium, 1999 (poster presentation)		

Examiner Signature		Date Considered	7/22/07
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/790,488
		Filing Date	March 1, 2004
		First Named Inventor	Sherman
		Group Art Unit	unassigned 1614
		Examiner Name	unassigned TIMOTHY BETTON
Sheet	4	of	6
		Attorney Docket Number	AM-101314USA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
748	L15	J.J. GIBBONS, et al., The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells <i>in vitro</i> and in nude mouse xenografts <i>in vivo</i> , Proceedings of the American Association for Cancer Research, March 1999, 301, #2000, v.40	
448	L16	B. GEOERGER, et al., Rapamycin analog CCI-779 inhibits growth of human medulloblastoma xenografts, Proceedings of the American Association for Cancer Research, March 1999, 603, #3978, v.40	
448	L17	B. GEOERGER, et al., Cytotoxic effects of rapamycin in human medulloblastoma cell lines and xenografts: as single agent or in combination chemotherapy, Proceedings of the American Association for Cancer Research, 1999, #296	
448	L18	J. ALEXANDRE, et al., Phase I Study of CCI-779, Novel Rapamycin Analog: Preliminary Results, Proceedings of the American Association for Cancer Research, March 2000, 613, #3897, v.41	
738	L19	M. HIDALGO, et al., Phase I and pharmacological study of CCI-779, a cell cycle inhibitor, Proceedings of the 11th NCI/EORTC/AACR Symposium, November 2000, 4548s, 6 (Supp.), #413	
738	L20	M. HIDALGO, et al., A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor, Annals of Oncology, October 2000, 133, 11(4)	
738	L21	E. RAYMOND, et al., CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: A phase I study utilizing a weekly intravenous schedule, Proceedings of the 11th NCI/EORTC/AACR Symposium, November 2000, Abstract 414	
738	L22	E. RAYMOND, et al., CCI-779, a Rapamycin Analog and Multifaceted Inhibitor of Signal Transduction: a Phase I Study, Proceedings of ASCO, 2000, 187a, 19, #726	
738	L23	E. RAYMOND, et al., CCI-779, a Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule, Proceedings of ASCO, 2000, 187a, 19, #728	
738	L24	M. HIDALGO, Phase I and Pharmacological Studies with the Rapamycin Analog CCI-779 Administered as a 30 Minute Infusion, NCI-CTEP Drug Development Meeting, October 1999	
738	L25	M. ABOU-GHARBIA, Medicinal Chemistry Approaches for Optimization of Early Leads in Drug Candidates: The Discovery of Calicheamicin, Rapamycin and EAA-090, International Conference on Pure and Applied Heterocyclic Chemistry, March 2000	
738	L26	R. LANGRETH, et al., Drug Progress on Hard-to-Treat Cancers Is Cited, The Wall Street Journal, November 17, 1999, vol. 234	

Examiner Signature		Date Considered	7/22/07
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/790,488		
		Filing Date	March 1, 2004		
		First Named Inventor	Sherman		
		Group Art Unit	unassigned 1614		
		Examiner Name	unassigned TIMOTHY BETTON		
Sheet	5	of	6	Attorney Docket Number	AM-101314USA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TLB	L27	B. GEOERGER, et al., Antitumor Activity of the Rapamycin Analog CCI-779 in Human Primitive Neuroectodermal Tumor/Medulloblastoma Models as Single Agent and in Combination Chemotherapy, Cancer Research, Vol. 4, No. 61, February 15, 2001, pages 1527-1532, XP-001079526	
TLO	L28	J. BONI, et al., Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors, European Journal of Cancer, Vol. 37, NR. Suppl. 6, page S68, XP001084492, October 2001	
TB	L29	GUPTA, R.A., et al., Combinations for Cancer Prevention, Nature Medicine, Vol. 6, No. 9, XP-002223840, September 2000	
TB	L30	TORRANCE, et al., Combinatorial Chemoprevention of Intestinal Neoplasia, Nature Medicine, Vol. 6, No. 8, XP-002223841, September 2000	
TB	L31	ALBERTS, et al., New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors, The Oncologist, Vol. 3, No. 1, pages 15-34, February 1998	
TB	L32	SCHWARTSMANN, Marine Organisms and Other Novel Natural Sources of New Cancer Drugs, Annals of Oncology, Vol. 11, No. 3, pages 23-243, XP-001070989, October 13, 2000	
TB	L33	PUNT, et al., A phase I Study of Escalating Doses of CCI-779 in Combination with 5-fluorouracil and Leucovorin in Patients with Advanced Solid Tumors, European Journal of Cancer, Vol. 37, No. Supplement 6, Page S17, October 2001	
TB	L34	CLACKSON, et al., Broad Anti-Tumor Activity of ap23573, an mTOR Inhibitor in Clinical Development, Proc. Am. Soc. Clin. Oncol. 22, page 220, abstract 882, 2003	
TB	L35	BASELGA, et al., CCI-779 study 204: Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results, December 19, 2003 (abstract presented to ASCO for presentation in June 2004)	
TB	L36	Y. SHI, et al., Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin <i>in Vitro</i> , Cancer Research, Vol. 55, 9, May 1, 1995, pages 1982-1988, XP-002040888	
TB	L37	GREENBERGER, et al., A New Irreversible Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Cancer, Clinical Cancer Research, Vol. 6, page 38, November 2000, XP-001120789	
TB	L38	CARTER, et al., Chemotherapy of Cancer, Second Edition, John Wiley & Sons, NY, NY, pages 362-365, 1981	

Examiner Signature		Date Considered	7/22/07
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.